Table 2.

Results of Cox regression analyses assessing the associations between baseline serum suPAR concentration and CKD progression, ESKD, worsening proteinuria, all-cause mortality in the African-American Study of Kidney Disease and Hypertension

Outcome	No. of events	Model 1: Adjusted for Demographics and AASK Trial Arm		Model 2: Model 1 Additionally Adjusted for Kidney Measures		Model 3: Model 2 Additionally Adjusted for Clinical Risk Factors
		HRa (95% CI)	P Value	HRa (95% CI)	P Value	HRa (95% CI)	P Value
CKD progression	363	1.71 (1.54 to 1.90)	<0.001	1.29 (1.14 to 1.46)	<0.001	1.26 (1.11 to 1.43)	<0.001
ESKD	271	1.91 (1.69 to 2.16)	<0.001	1.34 (1.15 to 1.55)	<0.001	1.36 (1.17 to 1.58)	<0.001
Doubling of UPCR to ≥220 mg/g	448	1.21 (1.10 to 1.34)	<0.001	1.06 (0.96 to 1.18)	0.26	1.07 (0.96 to 1.19)	0.23
All-cause mortality	218	1.50 (1.32 to 1.70)	<0.001	1.32 (1.14 to 1.53)	<0.001	1.25 (1.08 to 1.45)	0.003

Adjusting variables include demographics (age and sex), AASK trial arm (BP control goal and trial medication), kidney measures (UPCR and measured GFR), and clinical risk factors (history of heart disease, history of smoking, C-reactive protein, and APOL1 risk status) at baseline. CKD progression was defined as doubling of serum creatinine from baseline or ESKD (requiring dialysis or kidney transplantation). Worsening proteinuria was defined as pre-ESKD doubling of 24-hour UPCR to ≥220 mg/g. suPAR, soluble urokinase-type plasminogen activator receptor; AASK, the African American Study of Kidney Disease and Hypertension; HR, hazard ratio; 95% CI, 95% confidence interval; UPCR, 24-hour urine protein-to-creatinine ratio.

^aHR per SD higher log-transformed baseline serum suPAR concentration.